

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT06355934

Status RECRUITING
Sponsor AstraZeneca
Enrollment 52,121 participants

Key Eligibility Criteria

Inclusion (4)

- Patients aged \geq 18 years at study index date AND
- A reported diagnosis code for amyloidosis OR
- A claim for ATTR-specific treatment OR
- A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR

Exclusion (2)

- Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR
- At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments

Locations (26 total)

Research Site, Eden Prairie, Minnesota, United States
Research Site, Calgary, Alberta, Canada
Research Site, Beijing, China
... and 23 more locations